Stoke Therapeutics reported $420 million in cash, bolstered by a $65.7 million ATM sale, providing enough liquidity to fund its zorevunersen program through early 2028. The expanded runway reduces financing risk ahead of a rolling NDA submission expected in the first quarter of 2027, a key milestone for investors.
Key Highlights
- Cash balance $420.0 million after $65.7 million ATM infusion extends runway to early 2028
- Phase 3 EMPEROR enrollment completed at 162 patients; first week‑52 completions expected August 2026
- Q2 revenue $9.3 million, net loss $61.6 million ($0.93 per share) versus prior‑year loss of $23.5 million ($0.40 per share)
Stoke Therapeutics (NASDAQ: STOK) posted a cash balance of $420.0 million, up from $354.3 million, after securing $65.7 million in an at‑the‑market sale. The infusion of liquidity pushes the company's runway out to early 2028, ensuring it can sustain the costly development and potential commercialization of its candidate zorevunersen for Dravet syndrome. Investors see a fortified balance sheet that lowers the probability of dilutive financing before the anticipated regulatory filing.
The cash strength also supports expanded research activities across the pipeline, including early‑stage programs targeting autosomal dominant optic atrophy.
Cash War Chest Strengthened
The company’s cash position now sits at $420.0 million, comprising $354.3 million in existing reserves and an additional $65.7 million from a recent ATM transaction. This capital will cover operating expenses, clinical trial costs, and potential launch preparations for zorevunersen through early 2028. A strong balance sheet reduces reliance on external borrowing and mitigates the impact of any adverse market movements on the stock.
The infusion also allows Stoke to accelerate dose‑escalation activities in its STK-002 program without compromising cash flow. With a cash runway extending beyond the anticipated NDA filing, the firm gains strategic flexibility to respond to regulatory feedback. This financial cushion positions the company favorably against peers with tighter liquidity constraints.
Phase 3 EMPEROR Progress
Stoke completed enrollment of 162 patients in the global Phase 3 EMPEROR trial across the United States, United Kingdom, and Japan, meeting the primary analysis cohort size. As of July 31, roughly 145 participants have passed week 8, 80 have reached week 24, and 60 are approaching the week 28 primary endpoint assessment. No participants have discontinued treatment, underscoring favorable tolerability.
First patients are slated to hit the week 52 milestone in August 2026, with the key readout expected in the third quarter of 2027. Successful data readout will crystallize the efficacy claim needed for approval, and the lack of discontinuations suggests a strong safety profile that could accelerate regulatory acceptance.
Financial Performance Highlights
Revenue for the quarter fell to $9.3 million from $13.8 million a year earlier, reflecting the end of a $150.8 million licensing revenue stream recognized in the prior period. Net loss widened to $61.6 million, or $0.93 per share, compared with a $23.5 million loss ($0.40 per share) in the same quarter last year. Research and development expenses rose to $49.5 million from $25.9 million, driven by intensified activities around zorevunersen.
The earnings surprise, EPS of $‑0.79 beating the $‑0.84 consensus, offers a modest positive signal amid broader market weakness.
Upcoming Catalyst
Stoke’s next major milestone is the rolling New Drug Application slated for the first quarter of 2027, which will incorporate the Phase 3 EMPEROR readout due in the third quarter of 2027. Successful navigation of these regulatory steps will determine the timing of a potential U.S. launch by early 2028. Investors will monitor the outcomes of the upcoming FDA engagement and the Phase 3 data release, as both are decisive for the company’s valuation trajectory.
Peers Moving on This News
- Biohaven Ltd (BHVN) down 5.8%
- Iovance Biotherapeutics Inc (IOVA) up 0.8%
Analysis based on the Form 8-K filed 3 August 2026; figures verified against the filing and live market data.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.






Please wait processing your request...